Skip to content

Loading...

Search for:

Search

About
Our Science
Diseases
Development Program
- Resomelagon
  - Inflammatory and Autoimmune Diseases
    
    RA: The BEGIN Study
    
    RA: The EXPAND Study
    
    RA: The RESOLVE Study
    
    RA: The ADVANCE Study
    
    iMN: SynAct-CS003
  - Host-Directed Therapy in Viral Infections
    
    COVID-19: RESOVIR-1
    
    Dengue Fever: RESOVIR-2
- TXP-11
Investors
News & Media

ENG
SVE

Search for:

Search

Annual General Meeting 2025

27 May, 2025

The Annual General Meeting for 2025 was held on Friday May 27, 2025.

Documents

Minutes
Press release - Bulletin from the annual general meeting 2025 in SynAct Pharma AB May 27, 2025 - English
Notice of annual general meeting 2025 in SynAct Pharma AB April 24, 2025 - English
The Nomination Committee’s proposals and reasoned statement 2025
Proxy Form (AGM 2025)
Remuneration report 2024

About

Management
Board of Directors
Advisory Board
History
Governance
Code of Conduct
Career

SynactPharma-white

Advancing medicine trough
melanocortin activation

SynAct Pharma AB (publ)
Scheelevägen 2
SE-223 63 Lund
Sweden

Synact Pharma ApS
Dronninggårds Alle 136
2840 Holte
Denmark

About
Our Science
Diseases
Development Program
Investors
News & Media

Privacy Policy
Cookies

Get the latest news follow us on Linkedin

© 2025 SynAct Pharma AB. All right reserved.